Advice

following a full submission:

anakinra (Kineret®) is accepted for use within NHSScotland.

Indication under review: in adults, adolescents, children and infants aged eight months and older with a body weight of 10kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs).

Anakinra was superior to placebo in achieving a modified American College of Rheumatology paediatric (mACRpedi) 30 response in patients with SJIA reliant on corticosteroids for disease control. Anakinra and DMARDs were associated with a similar remission rate in patients with AOSD following eight weeks of treatment.

Medicine details

Medicine name:
anakinra (Kineret)
SMC ID:
SMC2104
Indication:
Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).
Pharmaceutical company
Swedish Orphan
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full submission
Status
Accepted
Date advice published:
08 October 2018